Company
Investment-firm
Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Stock symbol
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies999
ImmunoGen
ImmunoGen is a clinical-stage biotechnology company that develops antibody-based anticancer therapeutics.
Sector
Subsector
Keywords
Location
total rounds
total raised
Transgene
Transgene SA is a biotech company focused on immune-targeted therapies.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
MediGene
MediGene is a German biotech company developing immunotherapies to treat cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
Orion Biotechnology
Orion Biotechnology is developing novel formulations for life-threatening diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Financials
Funding Rounds7
Number of Funding Rounds
Money Raised
Their latest funding was raised on 14.09.2020. Their latest investor Sofinnova Investments. Their latest round Post-IPO Equity
Merck Sharp & Dohme Sweden AB
Merck is a biopharmaceutical company that develops and provides innovative medicines and vaccines to save and improve lives globally.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Investments3
Abacus Bioscience
Abacus Bioscience develops immunotherapies for chronic infectious diseases and cancers.
Sector
Subsector
Keywords
Location
total rounds
total raised
Pieris Pharmaceuticals
Pieris Pharmaceuticals is a clinical-stage biotech company that creates differentiated drugs using its proprietary Anticalin® technology.
Sector
Subsector
Keywords
Location
total rounds
total raised
Cogent Biosciences
Cogent Biosciences develops precision therapies for genetically defined diseases.
Sector
Subsector
Keywords
total rounds
total raised
Co-Investors
Investors4
Number of lead investors
Number of investors
Sofinnova Investments
Sofinnova Investments is a venture capital firm that specializes in funding and supporting Life Science and Technology start-ups.
Sector
Subsector
Location
count Of Investments
count Of Exists
New Enterprise Associates
NEA is a global venture capital firm that helps entrepreneurs build innovative businesses in technology and healthcare.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Paul Walker
Paul Walker joined NEA in 2008. He focuses on later-stage biotechnology and life sciences investments. Prior to joining NEA, Paul worked at MPM Capital as a General Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a portfolio manager at Franklin Templeton Investments. Paul received a BS in Biochemistry and Cell Biology from the University of California at San Diego, and holds the Chartered Financial Analyst designation. He is a board member of TESARO and a board observer of Sunesis and manages a number of NEA’s other late-stage and public investments.
current job
Takeda
Takeda Pharmaceutical Company Limited markets a range of original products in the healthcare industry.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Acquisitions1
Cascadian Therapeutics acquired by Seagen
acquirer
date
type
price
Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company that develops and sells therapeutic products for cancer treatment.
Sector
Subsector
Keywords
Location
total rounds
total raised
IPO & Stock Price
Seagen is registered under the ticker NASDAQ:SGEN . Their stock opened with in the 07.03.2001
Stock Symbol
ipo date
People
Founders1
Clay Siegall
Dr. Siegall co-founded Seattle Genetics in 1998 and is the company’s President, Chief Executive Officer and Chairman of the Board of Directors. Under his leadership, Seattle Genetics has built a diverse pipeline of antibody-based cancer therapies, including ADCETRIS (brentuximab vedotin) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in 2011. Dr. Siegall has also guided Seattle Genetics/ capital-raising activities, securing more than $675 million through public and private financings, including the company’s initial public offering in 2001. Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. He serves on the Board of Directors of Alder BioPharmaceuticals, a private biotechnology company. Dr. Siegall is an author on more than 70 publications and holds 15 patents. He received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.
current job
organization founded
Clay Siegall
Employee Profiles347
Lee Heeson
Executive Vice President, Commercial International
Muralikrishnan Sundararajan
Senior director - business application management
Christina Schwalbe
Global qc senior manager, operational excellence
Ken Wilhelm
Executive medical director medical affairs at seattle genetics
Ray Liao
Senior medical director, safety evaluation and risk management
James Henderson
Senior manager, clinical feasibility and analytics
Activity
Recent News41
The graph reveals the ratio (%) of positive news articles in a chosen time range